Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation. An overview showing Moderna’s diverse technological focuses map [Image courtesy: Moderna] The company publicly revealed two pipeline programs: mRNA-6007, an in vivo CAR-T candidate for autoimmune disease, and mRNA-2151, a multiplexed T-cell engager for ovarian cancer. The company revealed Lucy, an internal machine learning platform designed to run closed-loop experimental cycles. Moderna built its commercial foundation on a single modality, lipid nanoparticle-delivered mRNA for infectious disease vaccines. These announcements indicate that the company is now attempting to replicate that infrastructure logic across oncology…
At its recent annual Science Day, Moderna signalled a strategic expansion beyond its established vaccine and rare disease franchises, unveiling new programs in in vivo CAR-T and solid tumor oncology. The firm also revealed an AI-driven research platform it says will accelerate the pace of drug discovery across its pipeline. The company publicly revealed two…
The post Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform appeared first on Drug Discovery and Development.
US Pharma Marketing